Rovin Capital Biogen Inc. Transaction History

Rovin Capital

$240 Million
Q2 2024

A detailed history of Rovin Capital transactions in Biogen Inc. stock. As of the latest transaction made, Rovin Capital holds 2,741 shares of BIIB stock, worth $517,308. This represents 0.26% of its overall portfolio holdings.

Number of Shares

2,741

Previous 2,380 15.17%

Holding current value

$517,308

Previous $513,000 23.78%

% of portfolio

0.26%

Previous 0.21%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 18, 2024	BUY	$190.52 - $236.72 $68,777 - $85,455	361 Added 15.17%	2,741 $635,000
Q1 2024 Apr 22, 2024	BUY	$212.02 - $267.71 $67,422 - $85,131	318 Added 15.42%	2,380 $513,000
Q4 2023 Mar 12, 2024	BUY	$222.59 - $267.94 $106,843 - $128,611	480 Added 30.34%	2,062 $534,000
Q3 2023 Oct 25, 2023	SELL	$253.3 - $285.89 $41,794 - $47,171	-165 Reduced 9.44%	1,582 $407,000
Q2 2023 Aug 08, 2023	SELL	$275.25 - $318.06 $41,012 - $47,390	-149 Reduced 7.86%	1,747 $498,000
Q1 2023 Apr 05, 2023	SELL	$256.56 - $292.34 $137,772 - $156,986	-537 Reduced 22.07%	1,896 $527,000
Q4 2022 Jan 23, 2023	SELL	$252.44 - $306.72 $36,603 - $44,474	-145 Reduced 5.62%	2,433 $674,000
Q3 2022 Oct 25, 2022	SELL	$194.69 - $268.46 $10,318 - $14,228	-53 Reduced 2.01%	2,578 $688,000
Q2 2022 Jul 22, 2022	BUY	$187.54 - $223.02 $15,190 - $18,064	81 Added 3.18%	2,631 $537,000
Q1 2022 Jun 13, 2022	BUY	$193.77 - $244.14 $158,697 - $199,950	819 Added 47.31%	2,550 $537,000
Q4 2021 Feb 24, 2022	BUY	$223.92 - $287.77 $387,605 - $498,129	1,731 New	1,731 $415,000

Others Institutions Holding BIIB

# of Institutions

1,049

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $27.2B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rovin Capital , based on Form 13F filings with the SEC.

News

Stay updated on Rovin Capital with notifications on news.

Account